| Hazard Information | Back Directory | [Uses]
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research[1][2]. | [References]
[1] Sam Jackson, et al. Six months interim analysis of the phase 2 study of AL001 in frontotemporal dementia patients carrying a granulin mutation. Alzheimer's & DementiaVolume 17: Drug Development.
[2] Robert Paul, et al. AL001 Blocks the Sortilin/PGRN Interaction and is a Potential Therapy for FTD-GRN (4422). Neurology, April 13, 2021; 96 (15 Supplement). |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|